Basta M
Laboratory of Clinical Investigations, National Institute of Allergy and infectious Diseases, Bethesda, Maryland 20892, USA.
Clin Exp Immunol. 1996 May;104 Suppl 1:21-5.
High-dose intravenous immune globulin (IVIG) exerts a beneficial effect in a variety of immune disorders. One possible underlying mechanism of this effect could be interference with the complement system. This conclusion was based on the results obtained in animal models of complement-mediated pathology, in vitro complement assays and studies on related human diseases. Clearance of IgM-sensitized erythrocytes was specifically suppressed by IVIG treatment. The same therapy prevented pulmonary endothelial cell lesions, the hallmark of Forssman shock, in 75% of animals. All control animals, either untreated or injected with control reagents, died within minutes following induction of Forssman shock. In vitro uptake of C3b and C4b complement fragments onto corpusculate immune complexes was significantly inhibited by IVIG. Studies that involved patients suffering from disorders with pathogenesis similar to animal models of complement-mediated immune injury fully supported the hypothesis that IVIG interacts with activated complement components and prevents their deposition on target cells. The author's results suggest that IVIG can be an effective modulator of inappropriate complement attack.
大剂量静脉注射免疫球蛋白（IVIG）在多种免疫紊乱中发挥有益作用。这种作用的一种潜在机制可能是干扰补体系统。这一结论基于在补体介导的病理动物模型、体外补体检测以及相关人类疾病研究中获得的结果。IVIG治疗可特异性抑制IgM致敏红细胞的清除。同样的治疗方法在75%的动物中预防了福尔曼休克的标志性病变——肺内皮细胞损伤。所有未治疗或注射对照试剂的对照动物在诱导福尔曼休克后几分钟内死亡。IVIG显著抑制了C3b和C4b补体片段在颗粒状免疫复合物上的体外摄取。涉及发病机制与补体介导的免疫损伤动物模型相似的疾病患者的研究充分支持了IVIG与活化的补体成分相互作用并阻止其沉积在靶细胞上的假说。作者的结果表明，IVIG可能是不适当补体攻击的有效调节剂。
